The drug overcomes the 2 major resistance mechansisms of tetracycline: drug-specific efflux pump acquisition and ribosomal protection. Tigecycline is active against many gram-positive and -negative organisms, including methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and -resistant enterococci, and extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae. It is also active against many anaerobic bacteria, as well as atypical pathogens, including rapidly growing, nontuberculous mycobacteria. Tigecycline is concentrated in cells and is eliminated primarily via biliary excretion. Diminished renal function does not significantly alter its systemic clearance. Furthermore, tigecycline does not interfere with common cytochrome P450 enzymes, making pharmacokinetic drug interactions uncommon. It provides parenteral therapy for complicated skin/skin-structure and intra-abdominal infections. The only prominent adverse effects are associated with tolerability, most notably nausea and vomiting. Tigecycline will be most useful as empirical therapy for polymicrobial infections, especially in cases in which deep tissue penetration is needed or in which multidrug-resistant pathogens are suspected.
I N V I T E D A R T I C L E R E V I E W S O F A N T I -I N F E C T I V E A G E N T S aerobic gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus, vancomycin-resistant enterococci, and penicillin-resistant
Streptococcus pneumoniae, MIC 90 values range from 0.12 to 0.5 mg/mL [2] . In addition, both tetracycline-susceptible and -resistant strains have exhibited almost identical MIC values for tigecycline. Some of the MIC values of tigecycline may be higher than recorded values, because tigecycline requires a fresh medium for accurate MIC testing [3] . Nonetheless, almost 100% of the aforementioned organisms would be considered susceptible to tigecycline at the FDA susceptibility breakpoints of 0.25 and 0.5 mg/mL for streptococci and staphylococci, respectively. Similar MIC values for tigecycline have been observed for respiratory gram-negative pathogens, such as Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, and Chlamydophyla pneumoniae. Tigecycline's MIC value for Legionella species are high, but the drug is partially inactivated by the test medium. For Enterobacteriaceae, tigecycline's MIC 90 values for tetracycline-susceptible strains have ranged from 0.25 to 1 mg/mL [4] . However, tigecycline activity against tetracycline-resistant strains has been more variable. Although most tetracyclineresistant strains have tigecycline MIC values that are similar to those for tetracycline-susceptible isolates, a small percentage of tetracycline-resistant strains have tigecycline MIC values in the 2-16 mg/mL range. This is especially true for most strains of Proteus and Providencia species and for many strains of Morganella morganii [2, 4] . Studies of these isolates suggest that these strains have constitutively overexpressed multidrug efflux pump systems (e.g., AcrAB) for which tigecycline is a substrate [5, 6] . Tigecycline is active against most anaerobic bacteria, including Clostridium difficile, Fusobacterium species, Prevotella species, Poryphymonas species, and the Bacteroides fragilis group [2, 9] . The FDA susceptibility breakpoint to tigecycline for anaerobes is 4 mg/mL, which fits the MIC distribution of anaerobic organisms in the clinical trials. The drug is also highly active against Neisseria gonorrhoeae, Eikenella corrodens, and rapidly growing mycobacteria, such as Mycobacterium chelonae, Mycobacterium abscessus, and the Mycobacterium fortuitum group, which all had high MIC values to minocycline [2] .
Pharmacokinetics. Following intravenous administration, the drug has exhibited very linear pharmacokinetics from doses of 12.5-300 mg [10] . With doses of 100 mg, the initial mean maximum concentration in healthy volunteers was 0.91 ‫ע‬ mg/mL after a 1-h infusion. After multiple doses of 50 mg 0.22 every 12 h, the mean maximum concentration was 0.62 ‫ע‬ mg/mL [11] . The entire area under the curve (AUC) (mg 0.09 ϫ h/mL) after a single 100-mg dose was , whereas 4.87 ‫ע‬ 1.41 the AUC over 12 h with multiple doses of 50 mg every 12 h was . Age and sex did not affect the maximum concen-3.07 ‫ע‬ 0.38 tration, AUC, or other pharmacokinetic parameters [12] . Tigecycline is reported to have protein binding from 69%-87%.
Tigecycline has a large volume of distribution that varied from 7.2 to 8.6 L/kg with single and multiple doses [11] . The mean clearance ranged from 0.2 to 0.3 L/h/kg, with ∼8%-11% of the drug excreted in the urine as unchanged drug over 48 h. The major route of elimination appears to be through feces, via biliary excretion. Glucuronide conjugates of tigecycline, its epimer, and an N-acetyl-9-aminominocycline were the major metabolites found, in low concentrations, in feces, urine, and serum [11] . The mean terminal half-life was 37-38 h after a single dose of 100 mg or multiple doses of 50 mg. The pharmacokinetic profile of tigecycline is not significantly modified by renal impairment, hemodialysis, or mild hepatic impairment [11] . Moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment resulted in a 25% and 55% reduction in systemic clearance, respectively.
The AUC over 12 h (AUC 0-12 ) of tigecycline in blister fluid after multiple doses of 50 mg every 12 h was 74% of the AUC 0-12 in serum [13] . The AUC 0-12 of tigecycline in epithelial lining fluid of healthy volunteers was 32% higher than the AUC 0-12 value in serum [14] . One would expect higher AUC values with pneumonia. On the other hand, tigecycline concentrations in alveolar macrophages of healthy volunteers were 78-fold higher than in those found in serum. Tigecycline concentrations in neutrophils have also been 20-to 30-fold higher than extracellular concentrations of the drug. Tigecycline provides high intracellular concentrations in other tissues (such as lung and bowel) that exceed serum concentrations by 2-to 8-fold [11] . Tigecycline concentrations found in bone have been ∼35% of those found in serum.
Pharmacodynamic analysis. Tigecycline exhibits timedependent killing and has prolonged postantibiotic effects [15] . Dose fractionation studies in the neutropenic murine-thigh infection model suggest that the ratio of the 24-h AUC to the MIC (AUC 24 :MIC) analysis is the pharmacokinetic-pharmacodynamic index that best correlates with in vivo activity of tigecycline. The mean AUC 24 :MIC value required for a bacteriostatic effect with various strains of S. pneumoniae, S. aureus, and E. coli was around 20. The presence of neutrophils should reduce that value by 2-to 4-fold down to an AUC 24 :MIC of 5-10, as observed with other tetracyclines in this model. Recent pharmacodynamic analyses of clinical trial data observed an AUC 24 :MIC breakpoint of 12.5 in complicated skin and softtissue infections and 7 with Enterobacteriaceae and anerobes in complicated intra-abdominal infections [16, 17] . Patients who had AUC 24 :MIC values at or greater than these values had significantly better outcomes than those with lower values.
An AUC 24 :MIC target of 5-10 would be achieved with tigecycline for almost all of the common gram-positive pathogens and with most Enterobacteriaceae. Although pharmacodynamic values based on serum concentrations would not fully support the high FDA susceptibility breakpoints for Enterobacteriaceae and anaerobes, high tissue concentrations of tigecycline at infection sites or in abscesses could.
Tigecycline has been bactericidal with prolonged therapy against MRSA in the rat endocarditis model. It was primarily bacteriostatic against Enterococcus faecalis, including vancomycin-resistant strains, in both rat and rabbit endocarditis models [18] . Tigecycline was bactericidal against methicillinsusceptible S. aureus (MSSA) in the rabbit osteomyelitis model and exhibited good, but not excellent, activity in Legionella pneumophila pneumonia in guinea pigs [19] . The drug also showed adequate CSF penetration, and was bactericidal against a penicillin-resistant strain of S. pneumoniae in experimental meningitis studies in rabbits [20] .
CLINICAL EFFICACY
Two phase 3, randomized, double-blind studies evaluating the efficacy of tigecycline, compared with vancomycin plus aztreonam, have been conducted in hospitalized patients with complicated skin/skin-structure infections. Both studies had the same design, and a pooled analysis of the results from these clinical trials has been reported elsewhere [21] 
The overall clinical cure rates were similar (86.5% for tigecycline and 88.6% for vancomycin-aztreonam) in the 2 groups. Microbiological success rates were also comparable in the 2 treatment groups (86% vs. 88%). Similar eradication rates were observed in the 2 treatment groups in patients with monomicrobial and polymicrobial infections, as well as those patients who were bacteremic. Of note, tigecycline was as effective as vancomycin-aztreonam (78% vs. 76%) in eradicating strains of MRSA. Moreover, all 8 strains of B. fragilis isolated in the tigecycline treatment group were eradicated. No isolates developed a decreased susceptibility to tigecycline in this study.
A pooled analysis of 2 phase 3, double-blind, randomized studies in patients with complicated intra-abdominal infections has also been reported elsewhere [22] . In both of these trials, tigecycline (100 mg, followed by 50 mg every 12 h) was compared with imipenem-cilastatin (500 mg every 6 h). Treatment was for 5-14 days, and clinical response was evaluated at 12-42 days after therapy. The clinically evaluable population contained 1382 patients (585 received tigecycline, and 607 received imipenem-cilastatin), of whom 1262 had a pretherapy isolate recovered from their infection site. Complicated appendicitis (50%) was the most common infection diagnosis, followed by complicated cholecystitis (14%). Severely ill patients, such as those with malignancy, APACHE II scores 130, gangrenous cholecystitis, or necrotizing pancreatitis, were excluded from this study. The severity of illness was similar in each treatment group (APACHE II score, ∼6). Overall, clinical cure rates were similar (86%) in the 2 treatment groups. Bacterial eradication rates were also similar between groups. For E. coli, the most commonly isolated pathogen, eradication rates were 86% for tigecycline and 87% for imipenem-cilastatin. Twelve (80%) of 15 patients with ESBL-producing E.coli or Klebsiella pneumoniae achieved bacterial eradication after receiving tigecycline. Two patients had isolates (K. pneumoniae and M. morganii) that were initially susceptible to tigecycline but that were subsequently found to be resistant (MIC value for each, 8 mg/mL) following therapy; these patients experienced clinical failure. Eradication rates for anaerobic bacteria were similar to those for aerobic organisms. For example, tigecycline's eradication rates for isolates of B. fragilis and Clostridium perfringens were 78% and 95%, respectively. A similar success rate against these anaerobic pathogens was observed in patients who received imipenem-cilastatin. Forty patients who received tigecycline had concomitant bacteremia, and 33 (82%) of these patients experienced a clinical cure. Treatment failures with tigecycline were not associated with resistant isolates, and only 1 patient with E.coli bacteremia (MIC, 0.5 mg/mL) had a positive blood culture result after initiation of therapy. The clinical cure rate was 80% (40 of 50 patients) for patients with concomitant bacteremia who received imipenem-cilastatin.
In summary, monotherapy with tigecycline has exhibited noninferiority to other standard treatments for complicated skin/skin-structure and intra-abdominal infections. It is important to note that most patients studied had communityacquired infection. Furthermore, few patients had serious comorbid conditions, and each received surgical source control when indicated (e.g., drainage of abscesses and debridement of infected material). Bacteria resistant to tigecycline have been noted in clinical trials and have included isolates of K. pneumoniae, Escherichia cloacae, M. morganii, and Acinetobacter baumannii [23] .
SAFETY AND TOLERABILITY
Clinically significant organ toxicity has not been observed with tigecycline use during clinical trials. In dose-descending and multiple dose studies in healthy subjects (phase 1 investigations), no clinically relevant changes in laboratory parameters, blood pressure, or electrocardiogram intervals were observed [10, 14] . Transient elevations in alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels occurred in some test subjects. In a phase 2 clinical trial of 160 hospitalized patients with skin/skin-structure infections, there was 1 case each of paresthesia and allergy (itching) associated with tigecycline use [24] . Abnormal laboratory test results possibly related to tigecycline use were observed in only 9 patients. These results included an elevated serum transaminase level in 5 patients, an elevated serum alkaline phosphatase level in 2 patients, and an elevated blood urea nitrogen level in 1 patient. A total of 1383 patients received tigecycline in multicenter, double-blind, randomized clinical trials (phase 3). In patients treated with tigecycline for skin/skin-structure infections, no hematologic or serum chemistry abnormalities were associated with use of tigecycline [21] . Of note, activated partial thromboplastin or prothrombin time was prolonged in ∼3% of patients. In patients with complicated intra-abdominal infections, few clinically important or unexpected changes in any routine hematologic or serum chemistry test results, vital signs, or electrocardiogram data were associated with tigecycline treatment [22] . None of the deaths in patients who received tigecycline were associated with an adverse drug effect; however, because tigecycline has been studied in !2000 patients, rare adverse events may have occurred that were not documented during clinical investigations. Because of tigecycline's similarity to minocycline, potential adverse effects may include hepatitis, pancreatitis, vertigo, hearing loss, lupus erythematous-like syndrome, and hyperpigmentation. No safety data on long-term use of tigecycline have been published.
The most frequently reported adverse effects associated with the use of tigecycline are nausea and vomiting. These untoward effects are dose limiting and are not diminished by a slowing of the rate of drug infusion [10] . There does not appear to be a relationship between nausea produced by tigecycline and serotonin release [12] . Subjects who were fed or received antiemetics at the time of administration had improved tolerability of tigecycline [10, 14] . Older individuals (age, 175 years) and men also reported less nausea than did women and younger subjects [12] . In phase 3 clinical trials, nausea and vomiting occurred in 30% of older and male patients, and 20% of female and younger patients. Nausea as an adverse effect to tigecycline usually occurs in the first 1-2 days of treatment and is transient in most patients. The majority of cases of nausea and vomiting were reported to have been mild (patients were able to ingest food and water). In spite of these findings, close to 30% of patients with complicated skin/skin-structure infections received an antiemetic during tigecycline therapy. The overall discontinuation rate during tigecycline treatment was 5% and was most frequently associated with nausea (1.3%) and vomiting (1.0%). Diarrhea was also reported in a significant number of patients (13%) in phase 3 clinical trials, but no tigecyclinetreated patient tested positive for C. difficile toxin or developed C. difficile-associated diarrhea. One case of C. difficile-associated diarrhea was reported from a phase 2 clinical trial of patients with complicated intra-abdominal infections [25] .
Skin reactions with tetracyclines are not common but may be made manifest as pruritis, urticaria, and maculopapular rashes. Cross-sensitization occurs with this class of antibiotics; therefore, anyone reporting an allergy to one of these agents should be considered hypersensitive to tigecycline.
DOSING AND COST
The recommended dosage of tigecycline for the treatment of complicated intra-abdominal and skin/skin-structure infections in adults is 100 mg iv initially, followed by 50 mg iv every 12 h. Dosing guidelines in pediatric patients have not been established. Because of poor oral absorption qualities, tigecycline should not be given enterally. No dosage adjustment is necessary for renal or hepatic impairment unless the patient has severe hepatic dysfunction (Child Pugh C). Tigecycline is not a substrate, inhibitor, or inducer of common cytochrome P450 enzymes and is not highly protein bound. This suggests that pharmacokinetic drug interactions will be uncommon with tigecycline, although concomitant use with warfarin can decrease the clearance of both of warfarin's isomers. In patients who are receiving warfarin therapy, careful international normalized ratio monitoring is prudent while they are receiving tigecycline. Tigecycline has a Pregnancy Category D label and should not be given to pregnant women.
The acquisition cost of tigecycline is approximately $90 per day [26] . This daily cost is less than the purchase of intravenous linezolid, daptomycin, or meropenem but is more expensive than ertapenem and piperacillin/tazobactam. When used in long-term care facilities or for outpatient parenteral antibiotic therapy, reconstituted tigecycline can be stored for 6 h at room temperature and up to 24 h if refrigerated.
FORMULARY ISSUES
Currently, tigecycline has FDA-approved indications for the treatment of complicated skin/skin-structure and intra-abdominal infections. Although there are several antibiotics or combinations of agents that can be used to treat these infections, tigecycline is unique for its ability to be used as monotherapy for empirical coverage of various drug-resistant pathogens. It has antimicrobial activity against several multidrug-resistant bacteria, including vancomycin-resistant staphylococci and enterococci, Enterobacteriaceae that contain ESBLs, and carbapenen-resistant Acinetobacter species. At present, there is a paucity of clinical data supporting tigecycline's efficacy against infections caused by these multidrug-resistant organisms, with the exception of MRSA. In compassionate-use experience, tigecycline has been effective in the treatment of multidrugresistant strains of Acinetobacter species (Ellis Caplan, personal communication) [23] .
There is currently an ongoing debate as to whether the use of this new antimicrobial agent should be restricted to infectious diseases specialists or whether it should be made accessible to all hospital clinicians. The major argument against the expanded availability of tigecycline is the potential for the development of drug-resistant isolates. Although glycylcyclines are not affected by classical mechanisms of resistance to tetracyclines, intrinsic reduced susceptibility of tigecycline occurs in strains of P. aeruginosa and Proteus mirabilis as a result of the acquisition of multidrug efflux pumps [27] . Efflux pump systems associated with decreased tigecycline susceptibility have also been found in clinical strains of E. coli and K. pneumoniae.
An argument for the unrestricted availability of tigecycline is that other commonly used antimicrobials (fluoroquinolones, cephalosporins, and carbapenems) may be more prone to causing "collateral damage" in hospitalized patients [28, 29] . This adverse effect of antibiotic therapy can involve colonization or infection with organisms such as vancomycin-resistant enterococci, ESBL-producing bacteria, b-lactam-resistant Acinetobacter species, C. difficile, MRSA, and P. aeruginosa. The use of tigecycline could help to decrease the hospital burden on these other broad-spectrum antimicrobial agents. The impact of tigecycline on emergence of resistance in hospitalized patients is unknown at this time.
Tigecycline appears to have low potentials for organ toxicity and drug-drug interactions. These properties, along with twicedaily dosing and the lack of need to monitor renal function, make the use of this antibiotic relatively uncomplicated. One concern will be for patients who develop moderate-to-severe nausea and vomiting during tigecycline therapy. Antiemetics, such as metaclopramide and prochlorperazine, are effective in these patients, but they can add cost and potential adverse effects to patient care.
In summary, tigecycline will be most useful as empirical therapy for polymicrobial infections, especially in cases where deep tissue penetration is required or where multidrug-resistant pathogens are suspected. Use in patients with b-lactam or fluoroquinolone hypersensitivity or intolerance, in those with renal failure, or in those who are receiving numerous medications is also an important consideration. Tigecycline's lack of activity against P. aeruginosa and low serum concentrations will limit its use in some patient populations, such as those with neutropenic fever. Its potential for treating chronic infections in ambulatory care settings is an area currently under investigation.
